Xilio Therapeutics, Inc. 8-K

What Happened

• Xilio Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2026 and other business highlights in an 8‑K filed May 12, 2026 (Item 2.02).
• The full press release containing the results and highlights is furnished as Exhibit 99.1 to the Current Report on Form 8‑K.

Key Details

• Filing date: May 12, 2026.
• Quarter covered: quarter ended March 31, 2026 (Q1 2026).
• Press release included as Exhibit 99.1 to the Form 8‑K.
• The disclosure in the Form 8‑K (including Exhibit 99.1) is furnished, not filed, and therefore is not subject to Section 18 liability and is not automatically incorporated by reference into other filings.

Why It Matters

• This 8‑K is Xilio’s official public release of its quarterly earnings and business update; investors should review Exhibit 99.1 for the specific financial figures (revenue, expenses, net loss, cash position) and any operational or pipeline updates that could affect valuation.
• Because the release is furnished rather than filed, it provides timely information but isn’t subject to certain Exchange Act liabilities and won’t be automatically incorporated into future SEC filings unless specifically referenced.